You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Medtronic
Merck
Express Scripts
AstraZeneca

Last Updated: June 4, 2020

DrugPatentWatch Database Preview

COMBIVIR Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Combivir patents expire, and what generic alternatives are available?

Combivir is a drug marketed by Viiv Hlthcare and is included in one NDA.

The generic ingredient in COMBIVIR is lamivudine; zidovudine. There are twenty-nine drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the lamivudine; zidovudine profile page.

Drug patent expirations by year for COMBIVIR
Drug Prices for COMBIVIR

See drug prices for COMBIVIR

Recent Clinical Trials for COMBIVIR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Augusta UniversityPhase 4
Massachusetts General HospitalPhase 2
AIDS Clinical Trials GroupPhase 3

See all COMBIVIR clinical trials

Recent Litigation for COMBIVIR

Identify potential future generic entrants

District Court Litigation
Case NameDate
Glaxo Group Ltd. v. Lupin Ltd.2008-08-29
Plaintiff(s) v. Defendant(s)2008-01-31
Glaxo Group Ltd. v. Teva Pharmaceuticals USA Inc.2007-11-02

See all COMBIVIR litigation

Synonyms for COMBIVIR
[[(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxo-pyrimidin-1-yl)tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl] phosphono hydrogen phosphate
1-(3'-Azido-2',3'-dideoxy-beta-D-xylofuranosyl)thymine 5'-triphosphate
3'-Azido-2',3'-dideoxythymidine-5'- triphosphate
3'-Azido-2',3'-dideoxythymidine-5'-triphosphate
3'-azido-3'-deoxythymidine 5'-(tetrahydrogen triphosphate)
3'-Azido-3'-deoxythymidine 5'-triphosphate
3'-azido-3'-deoxythymidine triphosphate
3'-Azido-dTTP
3'-Azidothymidine triphosphate
3'-Deoxy-3'-azidothymidine triphosphate
3'-N3-dTTP
6RGF96R053
92586-35-1
AZddTTP
AZT triphosphate
Azt-TP
AZT-triphospate
AZTTP
BDBM50370476
CHEMBL193952
CTK5H1433
Dttp(3'N3)
DTXSID80239053
Erythro-azt-TP
FT-0615084
GLWHPRRGGYLLRV-XLPZGREQSA-N
LS-178176
N3dTTP
NSC742231
Q27265380
SCHEMBL19808965
Threo-azt-TP
Thymidine 5'-(tetrahydrogen triphosphate), 3'-azido-2', 3'-dideoxy-
Thymidine 5'-(tetrahydrogen triphosphate), 3'-azido-3'-deoxy-
UNII-6RGF96R053
ZDV-TP
Zidovudine 5'-triphosphate
Zidovudine triphosphate
ZINC13455082

US Patents and Regulatory Information for COMBIVIR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare COMBIVIR lamivudine; zidovudine TABLET;ORAL 020857-001 Sep 26, 1997 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for COMBIVIR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv Hlthcare COMBIVIR lamivudine; zidovudine TABLET;ORAL 020857-001 Sep 26, 1997   Start Trial   Start Trial
Viiv Hlthcare COMBIVIR lamivudine; zidovudine TABLET;ORAL 020857-001 Sep 26, 1997   Start Trial   Start Trial
Viiv Hlthcare COMBIVIR lamivudine; zidovudine TABLET;ORAL 020857-001 Sep 26, 1997   Start Trial   Start Trial
Viiv Hlthcare COMBIVIR lamivudine; zidovudine TABLET;ORAL 020857-001 Sep 26, 1997   Start Trial   Start Trial
Viiv Hlthcare COMBIVIR lamivudine; zidovudine TABLET;ORAL 020857-001 Sep 26, 1997   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for COMBIVIR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0513917 17/1998 Austria   Start Trial PRODUCT NAME: LAMIVUDIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, UND ZIDOVUDIN; REGISTRATION NO/DATE: EU/1/98/058/001 EU/1/98/058/002 19980318
0513917 98C0020 Belgium   Start Trial PRODUCT NAME: LAMIVUDINE/ZIDOVUDINE; REGISTRATION NO/DATE: EU/1/98/058/001 19980318
0513917 98C0018 Netherlands   Start Trial PRODUCT NAME: SAMARIUM LEXIDRONAM PENTASODIQUE; NAT. REGISTRATION NO/DATE: EU/1/97/057/001 19980205; FIRST REGISTRATION: CH - 54265 19971006
0382526 19675032 Germany   Start Trial PRODUCT NAME: LAMIVUDINE, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH GEEIGNETEN SALZES; NAT. REGISTRATION NO/DATE: EU/1/96/015/001-002 19960808 FIRST REGISTRATION: CH 53662 53663 19960228
0513917 SPC/GB98/019 United Kingdom   Start Trial PRODUCT NAME: A COMBINATION COMPRISING LAMIVUDINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND ZIDOVUDINE; REGISTERED: UK EU/1/98/058/001 19980318; UK EU/1/98/058/002 19980318
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Medtronic
Merck
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.